<DOC>
	<DOCNO>NCT00503477</DOCNO>
	<brief_summary>A Phase I open label dose escalation study assess safety tolerability AZD2171 follow single multiple oral dos patient Japan advance solid malignancy . In addition expand cohort multi-centre study phase NSCLC patient CRC patient</brief_summary>
	<brief_title>A Phase I Open Label Dose Escalation Study Safety Tolerability AZD2171 Solid Tumors Japan</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<criteria>advanced solid tumor life expectancy 12 week longer patient uncontrolled brain metastasis patient inappropriate laboratory test value patient poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Japan</keyword>
	<keyword>Phase I</keyword>
	<keyword>solid tumor</keyword>
	<keyword>AZD2171</keyword>
</DOC>